Paul Herron
Plus aucun poste en cours
Profil
Paul M.
Herron worked as a Finance Manager at DuPont Merck Pharmaceutical Co. from 1989 to 1994.
He then worked as a Director of Finance & Investor Relations at Immunomedics, Inc. from 1994 to 1997.
From 1997 to 1999, he served as the Chief Financial Officer at Sunpharm Corp.
He then worked as the Chief Financial Officer at Copharos, Inc. from 2000 to 2003.
Later, he served as the Chief Executive & Financial Officer at Osprey Pharmaceutical Co. and as the Chief Financial Officer & VP-Business Development at Altor BioScience Corp.
He also worked as a Principal at E.I.
du Pont de Nemours & Co. Mr. Herron holds an undergraduate degree from Trinity College (Connecticut) and an MBA from Duke University.
Anciens postes connus de Paul Herron
| Sociétés | Poste | Fin |
|---|---|---|
Copharos, Inc.
 Copharos, Inc. BiotechnologyHealth Technology Copharos, Inc. was developed imaging and therapeutics. The company was headquartered in Ponte Vedra Beach, FL. | Directeur Financier/CFO | 01/01/2003 |
Sunpharm Corp.
 Sunpharm Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sunpharm Corp. is a company that develops small molecule pharmaceutical products. The company is based in Jacksonville, FL. The company was founded by Harry Z. Rosengart. Sunpharm was acquired by GelTex Pharmaceuticals, Inc. on November 17, 1999 for $12.16 million. | Directeur Financier/CFO | 01/01/1999 |
| IMMUNOMEDICS, INC. | Directeur Financier/CFO | 01/01/1997 |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Directeur Financier/CFO | 01/01/1994 |
| E.I. du Pont de Nemours & Co. /Anchorage Systems/ | Corporate Officer/Principal | - |
Formation de Paul Herron
| Duke University | Masters Business Admin |
| Trinity College (Connecticut) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Sunpharm Corp.
Sunpharm Corp. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sunpharm Corp. is a company that develops small molecule pharmaceutical products. The company is based in Jacksonville, FL. The company was founded by Harry Z. Rosengart. Sunpharm was acquired by GelTex Pharmaceuticals, Inc. on November 17, 1999 for $12.16 million. | Health Technology |
Copharos, Inc.
Copharos, Inc. BiotechnologyHealth Technology Copharos, Inc. was developed imaging and therapeutics. The company was headquartered in Ponte Vedra Beach, FL. | Health Technology |
| Osprey Pharmaceutical Co. | Health Technology |
Altor BioScience Corp.
 Altor BioScience Corp. Pharmaceuticals: MajorHealth Technology Altor BioScience Corp. operates as a biopharmaceutical company which develops therapeutic products for the treatment of cancer. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer and ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury. The company was founded by Hing C. Wong in 2002 and is headquartered in Miramar, FL. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
| E.I. du Pont de Nemours & Co. /Anchorage Systems/ | Process Industries |
